As the global economy mends, the 2021 growth of Oral Hypoglycemic Agents will have significant change from previous year. According to our (LP Information) latest study, the global Oral Hypoglycemic Agents market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Oral Hypoglycemic Agents market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Oral Hypoglycemic Agents market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Oral Hypoglycemic Agents market, reaching US$ million by the year 2028. As for the Europe Oral Hypoglycemic Agents landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Oral Hypoglycemic Agents players cover Eli Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., and AstraZeneca plc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Hypoglycemic Agents market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Liquid
Capsule
Tablet
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Eli Lilly and Company
Janssen Pharmaceuticals
Astellas Pharma Inc.
AstraZeneca plc
Sanofi S.A.
Takeda
Pfizer Inc
Beohringer Ingelgeim
Merk and Co.
Bristol Myers Squibb
Novartis International AG
Abbott Laboratories
Biocon Limited